Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial

Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial

Abstract Background Tenofovir disoproxil fumarate (TDF) in combination with other antiretroviral (ARV) drugs has been in clinical use for HIV treatment since its approval in 2001. Although the effectiveness of TDF in preventing perinatal HIV infection is well established, information about renal saf...

Full description

Bibliographic Details
Main Authors: Kristin Baltrusaitis, Bonus Makanani, Camlin Tierney, Mary Glenn Fowler, Dhayendre Moodley, Gerhard Theron, Lynette H. Nyakudya, Musunga Tomu, Lee Fairlie, Kathleen George, Barbara Heckman, Kevin Knowles, Renee Browning, George K. Siberry, Taha E. Taha, Lynda Stranix-Chibanda, for the PROMISE P1084s Study Team
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Infectious Diseases
Subjects:
HIV/AIDS
Antiretroviral therapy
Renal function
Pregnancy
Prevention of perinatal HIV transmission
Online Access:https://doi.org/10.1186/s12879-022-07608-8

Internet

https://doi.org/10.1186/s12879-022-07608-8

Similar Items